关注并星标CPHI制药在线近日,和誉医药自主研发的首款国产CSF-1R抑制剂盐酸匹米替尼胶囊,正式提交新药上市申请,用于需要系统性治疗的腱鞘巨细胞瘤(TGCT)成人患者。这一消息迅速引发行业高度关注,背后的6亿美金全球授权交易更是成为焦点。作为一款全新的口服、高选择性且高效的小分子CSF-1R抑制剂,匹米替尼精准针对集落刺激因子1受体(CSF-1R)。这一靶点在肿瘤微环境中扮演关键角色,尤其是在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.